Patient Perspectives Following a One-Week Medication Washout in Early-Stage Parkinson’s Disease Patients
Background/Objectives: Therapeutic washout protocols, where Parkinson’s disease (PD) patients discontinue their medication, are used in clinical trials to evaluate disease progression without the overt influence of symptomatic treatments. While prior washout studies focused on clinical outcomes, the participant experiences of undergoing an extended washout have not been examined. This study characterizes early-stage PD participants’ expectations, symptom experiences, emotional responses, and reflections following a one-week medication washout. Methods: Twenty early-stage PD participants enrolled in a one-week washout study (15 M/5 F; aged 65.7 ± 6.7 years; medication duration 1.8 ± 0.8 years; LEDD 490 ± 414 mg). Semi-structured interviews (~1 h) were audio-recorded, transcribed, and coded by trained coders. Transcripts were analyzed using an inductive–deductive approach to identify common themes and develop a conceptual framework. Results: All 20 participants were interviewed, including one who withdrew on day 5 due to intolerable symptoms. Recalled expectations ranged from confidence to fear of symptom exacerbation, and reassurance from study personnel reduced pre-washout anxiety. Symptoms included sleep disruption, restless legs symptoms, stiffness, tremor, and progressive motor decline that often intensified in the latter half of the week. Emotional responses ranged from frustration and isolation to equanimity. Upon resuming medications, recovery timelines varied. Many participants gained new insight into their medication’s efficacy, and some perceived their unmedicated state as a glimpse of how they might function as their disease progresses. Conclusions: This study provides the first characterization of participant experiences following a one-week medication washout in early-stage PD. These perspectives can inform washout protocol design, participant support, and retention in future clinical trials.
Authors
- David Charles
- David G. Schlundt (ORCID: https://orcid.org/0000-0001-7069-9644)
- Sheffield Sharp (ORCID: https://orcid.org/0000-0002-0437-9172)
- Mallory L. Hacker (ORCID: https://orcid.org/0000-0003-1498-4509)
- Kian Pazira (ORCID: https://orcid.org/0009-0000-5767-9956)
- Kemberlee R. Bonnet (ORCID: https://orcid.org/0000-0003-4046-3408)
- Leeza Kopaeva
- Thomas Davis (ORCID: https://orcid.org/0000-0002-1642-9288)
- Owen Dong
- Liliana Venditti
- Han Nguyen (ORCID: https://orcid.org/0009-0008-5308-1728)
- Haley Kling
- Kevin Cannard
- Ella Tobias
Institutions
- Vanderbilt University (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Brain Sciences
- Published
- 2026-11-20
- DOI
- https://doi.org/10.3390/brainsci16111277
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- National Institute on Aging
- National Center for Advancing Translational Sciences